Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/34017
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSayıner, Abdullah-
dc.contributor.authorÇilli, Aykut-
dc.contributor.authorKılınç, Oğuz-
dc.contributor.authorSakar Coşkun, Aysın-
dc.contributor.authorHazar, Armağan-
dc.contributor.authorKöktürk, Nurdan-
dc.contributor.authorFiliz, Ayten-
dc.contributor.authorPolatlı, Mehmet-
dc.contributor.authorTaşbakan, Sezai-
dc.contributor.authorKaraboğa, Burcu-
dc.date.accessioned2023-09-25T08:51:15Z-
dc.date.available2023-09-25T08:51:15Z-
dc.date.issued2017-
dc.identifier.citationÇetinoğlu, E. D. vd. (2017). ''Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation'' Human Vaccines & Immunotherapeutics, 13(9), 2072-2077.en_US
dc.identifier.issn2164-5515-
dc.identifier.issn2164-554X-
dc.identifier.urihttps://doi.org/10.1080/21645515.2017.1339851-
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/21645515.2017.1339851-
dc.identifier.urihttp://hdl.handle.net/11452/34017-
dc.description.abstractBackground: Previous reports have shown that vaccination rates of adult at-risk populations are low in Turkey. There are differing reports with regards to the effectiveness of the influenza and the pneumococcal polysaccharide vaccine (PPSV23) on the clinical outcomes of community acquired pneumonia (CAP). The purpose of this study was to analyze the influenza (FV) and pneumococcal vaccination (PV) status, the factors that influence the receipt of influenza/pneumococcal vaccine and the effects of prior vaccination on the clinical outcomes in adults hospitalized with CAP. Patients and Methods: Patients hospitalized with CAP between March 2009 and October 2013 and registered at the web-based Turkish Thoracic Society Pneumonia Database (TURCAP) were included in this multicentric, observational study. Of a total of 787 cases, data were analyzed for 466 patients for whom self-reported information on PV and FV was available. Results: In this adult population with CAP, the vaccination rate with both the pneumococcal and influenza vaccines was found to be 6%. Prior FV was found to be the sole variable that was associated with the receipt of PV [OR 17.8, 95% CI (25-75:8.56-37.01), p < 0.001]. Conversely, being vaccinated with PPSV23 was the only predictor of receipt of FV [OR 18.1, 95% CI (25 - 75:8.75 - 37.83), p < 0.001]. Compared to the unvaccinated cases, the chest radiograms of the vaccinated patients revealed less consolidation. The latter also reported fatigue, muscle pain and gastrointestinal symptoms less frequently. Although there was a trend for lower 30-day mortality and for lower rates of intensive care unit (ICU) admission, these did not reach statistical significance. A pneumonia severity index (PSI) score >= 90, CURB-65 score >= 3 and multilobar involvement, but not the vaccination status, were identified as independent determinants of ICU admission. Conclusions: This study showed that, among patients hospitalized with CAP, the FV and/or PV rates are low. Prior vaccination does not appear to significantly affect the clinical outcomes.en_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBiotechnology & applied microbiologyen_US
dc.subjectImmunologyen_US
dc.subjectAdultsen_US
dc.subjectCommunity-aquired pneumoniaen_US
dc.subjectInfluenza vaccinationen_US
dc.subjectPneumococcal polysaccharide vaccinationen_US
dc.subjectVaccination statusen_US
dc.subjectPolysaccharide vaccineen_US
dc.subjectPreventing pneumoniaen_US
dc.subjectProspective-cohorten_US
dc.subjectEtiologic agentsen_US
dc.subjectOlder-adultsen_US
dc.subjectOutcomesen_US
dc.subjectImmunizationen_US
dc.subjectMortalityen_US
dc.subjectTurkeyen_US
dc.subjectDeathen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshCommunity-acquired infectionsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHospitalizationen_US
dc.subject.meshHumansen_US
dc.subject.meshInfluenza vaccinesen_US
dc.subject.meshInfluenza, humanen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPneumococcal vaccinesen_US
dc.subject.meshPneumoniaen_US
dc.subject.meshPneumonia, pneumococcalen_US
dc.subject.meshRisk factorsen_US
dc.subject.meshSeverity of illness indexen_US
dc.subject.meshStreptococcus pneumoniaeen_US
dc.subject.meshTurkeyen_US
dc.subject.meshVaccinationen_US
dc.subject.meshVaccination coverageen_US
dc.subject.meshYoung adulten_US
dc.titlePneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentationen_US
dc.typeArticleen_US
dc.identifier.wos000413705700025tr_TR
dc.identifier.scopus2-s2.0-85025818876tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.tr_TR
dc.identifier.startpage2072tr_TR
dc.identifier.endpage2077tr_TR
dc.identifier.volume13tr_TR
dc.identifier.issue9tr_TR
dc.relation.journalHuman Vaccines and Immunotherapeuticsen_US
dc.contributor.buuauthorÇetinoğlu, Ezgi Demirdöğen-
dc.contributor.buuauthorUzaslan, Esra-
dc.contributor.researcheridAAI-1004-2021tr_TR
dc.relation.collaborationYurt içitr_TR
dc.identifier.pubmed28708954tr_TR
dc.subject.wosBiotechnology & applied microbiologyen_US
dc.subject.wosImmunologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid14062849300tr_TR
dc.contributor.scopusid8761653500tr_TR
dc.subject.scopusPneumococcal Vaccines; CD4 Lymphocyte Count; Human Immunodeficiency Virus 1en_US
dc.subject.emtreeInfluenza vaccineen_US
dc.subject.emtreePneumococcus vaccineen_US
dc.subject.emtree23-valent pneumococcal capsular polysaccharide vaccineen_US
dc.subject.emtreeInfluenza vaccineen_US
dc.subject.emtreePneumococcus vaccineen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChronic obstructive lung diseaseen_US
dc.subject.emtreeClinical outcomeen_US
dc.subject.emtreeCommunity acquired pneumoniaen_US
dc.subject.emtreeFatigueen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGastrointestinal symptomen_US
dc.subject.emtreeHospital admissionen_US
dc.subject.emtreeHospitalizationen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfluenza vaccinationen_US
dc.subject.emtreeIntensive care uniten_US
dc.subject.emtreeLength of stayen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMortalityen_US
dc.subject.emtreeMyalgiaen_US
dc.subject.emtreeCbservational studyen_US
dc.subject.emtreePneumococcal vaccinationen_US
dc.subject.emtreePneumonia Severity Indexen_US
dc.subject.emtreeScoring systemen_US
dc.subject.emtreeThorax radiographyen_US
dc.subject.emtreeVaccinationen_US
dc.subject.emtreeVery elderlyen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeCommunity acquired infectionen_US
dc.subject.emtreeHospitalizationen_US
dc.subject.emtreeImmunologyen_US
dc.subject.emtreeInfluenzaen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreePneumoniaen_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeSeverity of illness indexen_US
dc.subject.emtreeStreptococcus pneumoniaen_US
dc.subject.emtreeStreptococcus pneumoniaeen_US
dc.subject.emtreeVaccinationen_US
dc.subject.emtreeVaccination coverageen_US
dc.subject.emtreeYoung adulten_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Çetinoğlu_vd_2017.pdf686.81 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons